ArticleNeurological research and practice2026
Biomarker-based assessment of cerebral small vessel disease progression after ischemic stroke - a prospective cohort study (MA-BIO).
Article in Neurological research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebral small vessel disease (CSVD) is a leading cause of ischemic stroke and vascular cognitive impairment, yet currently lacks clinically established biomarkers for monitoring disease activity. While clinical routine magnetic resonance imaging (MRI) can provide quantitative measures of structural brain changes, it does not capture ongoing pathophysiological processes. Blood-based biomarkers offer a minimally invasive approach to detect dynamic changes in CSVD and may provide novel insights into mechanisms of progression and potential targets for intervention. This study aims to evaluate longitudinal trajectories of candidate blood biomarkers and their association with MRI-derived markers and cognitive outcomes in patients with CSVD.
methodsIn this single-center, prospective observational cohort study at the University Hospital Ulm, Germany, up to 180 adults with MRI-proven evidence of CSVD will be recruited and stratified into three groups: (1) CSVD without acute ischemic stroke, (2) CSVD with acute lacunar ischemic stroke, and (3) CSVD with territorial ischemic stroke. Participants will undergo comprehensive assessments at baseline, at 3, 6, and 12 months after enrollment. The primary outcome is defined as longitudinal changes of White Matter Hyperintensities (WMH) volumes. Secondary outcomes upon one year include DTI-derived measures, changes in blood biomarkers, cognitive performance, clinical functional measures, and incidence of new cerebrovascular events. Imaging, neurovascular ultrasound, and neuropsychological assessments will be conducted using standardized protocols. Clinical primary and secondary outcomes will be correlated to post-mortem CSVD pathology in the brain in prospectively studied patients, who have consented to autopsy. DISCUSSION: By integrating blood-based biomarkers with advanced imaging and longitudinal cognitive assessments, this study aims to advance our understanding of CSVD pathophysiology and may identify biomarkers of disease activity. Our findings hopefully inform future precision-medicine approaches and novel therapeutic strategies.
trial registrationGerman Clinical Trials Registry (DRKS00038936), registered February 3, 2026.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.